Abstract
Breast cancer has a prodigious capacity to metastasize to bone. In women with advanced breast cancer and bone metastases, bisphosphonates reduce the incidence of hypercalcaemia and skeletal morbidity. Recent clinical findings suggest that some bisphosphonates reduce the tumour burden in bone with a consequent increase in survival, raising the possibility that bisphosphonates may have a direct effect on breast cancer cells. We have investigated the in vitro effects of bisphosphonates zoledronate, pamidronate, clodronate and EB 1053 on growth, viability and induction of apoptosis in three human breast cancer cell lines (MDA-MB-231, Hs 578T and MCF-7). Cell growth was monitored by crystal violet dye assay, and cell viability was quantitated by MTS dye reduction. Induction of apoptosis was determined by identification of morphological features of apoptosis using time-lapse videomicroscopy, identifying morphological changes in nucleis using Hoechst staining, quantitation of DNA fragmentation, level of expression of bcl-2 and bax proteins and identification of the proteolytic cleavage of Poly (ADP)-ribose polymerase (PARP). All four bisphosphonates significantly reduced cell viability in all three cell lines. Zoledronate was the most potent bisphosphonate with IC50values of 15, 20 and 3 μM respectively in MDA-MB-231, MCF-7 and Hs 578T cells. Corresponding values for pamidronate were 40, 35 and 25 μM, whereas clodronate and EB 1053 were more than two orders of magnitude less potent. An increase in the proportion of cells having morphological features characteristic of apoptosis, characteristic apoptotic changes in the nucleus, time-dependent increase in the percentage of fragmented chromosomal DNA, down-regulation in bcl-2 protein and proteolytic cleavage of PARP, all indicate that bisphosphonates have direct anti-tumour effects on human breast cancer cells. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN and Sankey RR (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289: 1379–1384
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488–493
Boonecamp PM, van der Wee-Pais LJA, van Wijk-van Lennep MML, Thesing CW and Bijvoet OL (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. J Bone Miner Res 1: 27–39
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thomson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890–3894
Bossy-Wetzel E, Newmeyer DD and Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17: 37–49
Boyde A, Maconnachie E, Reid SA, Delling G and Mundy GR (1986) Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc IV: 1537–1554
Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Analyt Biochem 72: 248–254
Busch M, Rave-Frank M, Hille A and Duhmke E (1998) Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 3: 427–431
Cardone MH, Roy N, Stennicke NR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC (1998) regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318–1321
Cory AH, Owen TC, Barltrop JA and Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207–212
Coxen FP, Benford HL, Russell RGG and Rogers MJ (1998) Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54: 631–638
Dbaibo GS, Perry DK, Gamard CJ, Platt R, Poirier GG, Obeid LM and Hannun YA (1997) Cytokine response modifier a (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: crmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 185: 481–490
Diel IJ, Solomayer E, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357–363
Duke RC and Cohen JJ (1992) Morphological, biochemical, and flow cytometric assays of apoptosis. Current Protocols in Immunology (suppl. 3) Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds) pp. 3.17.1–3.17.16, Green/Wiley: New York
Fleisch H (1997) Bisphosphonates in bone disease, 3rd edn Parthenon Publishing Group: New York
Frith JC, Monkkonen J, Blackburn GM, Russell RGG and Rojers M (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358–1367
Golstein P (1997) Controlling cell death. Science 275: 1081–1082
Hall DG and Stoica G (1994) Effects of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9: 221–230
Hortobagyi GN, Theriault RL, Lipton A Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K and Reitsma DJ (1998) Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038–2044
Hughes DE, MacDonald BR, Russell RGG and Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930–1935
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478–1487
Kanis JA, Urwin GH, Gray RE, Beneton MN, McCloskey EV, Hamdy NA and Murray SA (1987) Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med 82: 55–70
Kanis JA, Powles T, Paterson AHG, McCloskey EV and Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19: 663–667
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG (1993) Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976–3985
Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC (1994) Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347
Lin JH, Duggan DE, Chen IW and Ellsworth RL (1991) Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19: 926–932
Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H and Bijvoet OLM (1988) Migration and phenotypic transformation of osteoclast precursors into mature osteoclast the effect of a bisphosphonate. J Bone Miner Res 3: 185–192
Luckman SP, Coxon FP, Ebetino FH, Russell RGG and Rojers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure–activity relationships in J774 macrophages. J Bone Miner Res 13: 1668–1678
Marzo I, Susin SA, Petit PX, Ravagnan L, Brenner C, Larochette N, Zamazmi N and Kroemer G (1998) Caspases disrupt mitochondrial membrane barrier function. FEBS Lett 427: 198–202
McConkey DJ and Orrenius S (1996) Signal transduction pathways in apoptosis. Stem Cells 14: 619–631
Mundy GR and Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339: 398–400
Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerises in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell 80: 285–291
Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S (1993) Double-blinded controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59–65
Plasmans CMT, Kuypers W and Slooff TJJH (1978) The effect of ethanal-hydroxy-1,1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop 132: 233–243
Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC and Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51: 3059–3061
Powles TJ, Paterson AHG and Nevantaus A (1998) Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Prog Proc Soc Clin Oncol 17: 123a
Reed J (1994) bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6
Ryzen E, Martodam R, Troxell M, Benson A, Paterson A, Shepard K and Hicks R (1985) Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med 145: 449–452
Sasaki A, Boyse BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR and Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551–3557
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA (1991) Bisphosphonates action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095–2105
Selander KS, Monkkonen Karhukorpi E, Harkonen P, Hannuniemi R and Vaananen KK (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50: 1127–1138
Shipman CM, Rojers MJ, Apperley JF, Russell RGG and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 98: 665–672
Shipman CM, Croucher PI, Russell RGG, Helfrich MH and Rogers MJ (1998) The bisphosphonates incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the Mevalonate pathway. Cancer Res 58: 5294–5297
Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM (1995) Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 80: 801–809
Townsend P, Villanova I, Uhlmann E, Knolie J, Peyman A, Amling M, Baron R, Horton MA and Teti A (1997) αvintegrin antisense oligodeoxynucleotides induce detachment and apoptosis of osteoclast and breast carcinoma cell. Proceedings from the 19th Annual Meeting of the American Society for Bone Miner Research S252
Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698–704
Vitale M, Matola TD, Rossi G, Laezza C, Fenzi G and Bifulco M (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endo 140: 698–704
Wingen F, Eichmann T, Manegold C and Krempien B (1986) Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol 111: 35–41
Wosikowski K, Kung W, Hasmann M, Loser R and Eppenberger U (1993) Inhibition of growth-factor-activated proliferation by anti-oestrogen and effects of on early gene expression of MCF-7 cells. Int J Cancer 53: 290–297
Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555–556
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Senaratne, S., Pirianov, G., Mansi, J. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82, 1459–1468 (2000). https://doi.org/10.1054/bjoc.1999.1131
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1131
Keywords
This article is cited by
-
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies
Medical Oncology (2021)
-
Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo
Pathology & Oncology Research (2020)
-
Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines
Molecular Biology Reports (2020)
-
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Cancer Cell International (2019)
-
Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells
Calcified Tissue International (2019)